Recruiting studies: Myelodysplastic Syndrome With Excess Blasts 2

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

BXCL701 Phase 1 R/R Acute Myeloid Leukemia or Myelodysplastic Syndrome
Phase 1 · 1 location(s) · Eric Stephen Winer, MD · NCT05703542 Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS
Phase 1/Phase 2 · 3 location(s) · ARCE Therapeutics, Inc. · NCT06680752 Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Pati
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT00801489 Oral-ATO for TP53-mutated Myeloid Malignancies
Phase 2 · 1 location(s) · The University of Hong Kong · NCT06778187 Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Pa
Phase 1/Phase 2 · 34 location(s) · Aptose Biosciences Inc. · NCT03850574 Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT
Phase 1/Phase 2 · 1 location(s) · Children's Hospital of Philadelphia · NCT06839456

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.